ProCE Banner Activity

Generalized Pustular Psoriasis: Diagnosis and Treatment Options

Clinical Thought

A diagnosis of life-threatening generalized pustular psoriasis (GPP) requires the exclusion of several other diagnoses presenting with pustules. In this commentary Alice Gottlieb, MD, PhD discusses the importance of an early and accurate diagnosis, which laboratory tests are helpful, and the newest, targeted treatment option available.


In Collaboration With Clinical Care Options, LLC

Released: September 16, 2022

Expiration: September 15, 2023

Begin Activity

Share

Faculty

Alice Gottlieb

Alice Gottlieb, MD, PhD

Clinical Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Medical Director
Department of Dermatology
Mount Sinai-Union Square
New York, New York

Acknowledgement

This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Dermatologists and APPs and nurses who practice in dermatology.

Disclosure

Alice Gottlieb, MD, PhD: consultant/advisor: AnaptsysBio, Amgen, Avotres Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb Co, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries, UCB; stock options: Xbiotech (for a rheumatoid arthritis program); research (paid to institution): AnapytsysBio, Bristol-Myers Squibb, Janssen, Novartis, Ortho, Sun Pharmaceutical, UCB.

Format

ClinicalThought

Additional Information

Program Medium

This program has been made available online.